- Companies continue to work collaboratively to advance
NRX-101 in bipolar depression with suicidality
- Lotus notes that NRx has "achieved a significant milestone
by completing enrollment for its phase 2b/3 trial of NRX-101 in suicidal
treatment-resistant bipolar depression. The readout for this trial
is anticipated in Q2 of this year."
- Productive partnership aims to accelerate NRX-101 to
patients in need
- Lotus further reported revenues of NT$1996, a 45% month over month
increase.
RADNOR,
Pa., Feb. 9, 2024 /PRNewswire/ -- NRx
Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the
"Company"), a clinical-stage biopharmaceutical company, today
announced that its Asia Pacific
strategic partner Lotus Pharmaceutical Co. Ltd (1975.TW) identified
enrollment completion of the NRx clinical trial in bipolar
depression as a material event in is February 7 financial filing.[1] Lotus
provides the Asia Pacific
component of NRx's global partnership with Alvogen, Inc.
Lotus reported in the accompanying press release that "Lotus
Pharmaceutical's strategic partner, NRX Pharmaceuticals, has
achieved a significant milestone by completing enrollment for its
phase 2b/3 trial of NRX-101 in
suicidal treatment-resistant bipolar depression. The readout for
this trial is anticipated in Q2 of this year."
"We at NRx are honored that Lotus has focused its resources on
helping us advance NRX-101 for the benefit of patients in the
Asia Pacific region. As reported
by the World Health Organization, suicidal depression is a
significant public health crisis in Pacific rim countries[2], just
as it is in the US," said Stephen
Willard, Chief Executive Officer of NRx Pharmaceuticals. "We
recently held very productive meetings at the JP Morgan conference
in San Francisco; we share a
mutual commitment to bringing a lifesaving treatment to patients
who have been excluded from the clinical trials of all known
antidepressants and whose only approved treatment today is
electroshock therapy."
NRx anticipates further updates regarding its global
partnerships in the coming days.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical
company developing therapeutics based on its NMDA platform for the
treatment of central nervous system disorders, specifically
suicidal bipolar depression, chronic pain and PTSD. The Company is
developing NRX-101, an FDA-designated investigational Breakthrough
Therapy for suicidal treatment-resistant bipolar depression and
chronic pain. NRx has partnered with Alvogen and Lotus around the
development and marketing of NRX-101 for the treatment of suicidal
bipolar depression. NRX-101 additionally has potential to act as a
non-opioid treatment for chronic pain, as well as a treatment for
complicated UTI.
NRx has recently announced plans to submit a New Drug
Application for NRX-100 (IV ketamine) in the treatment of suicidal
depression, based on results of well-controlled clinical trials
conducted under the auspices of the US National Institutes of
Health and newly obtained data from French health authorities,
licensed under a data sharing agreement. NRx was awarded Fast Track
Designation for development of ketamine (NRX-100) by the US FDA as
part of a protocol to treat patients with acute suicidality.
Cautionary Note Regarding Forward-Looking Statements
This announcement of NRx Pharmaceuticals, Inc. includes
"forward-looking statements" within the meaning of the "safe
harbor" provisions of the U.S. Private Securities Litigation Reform
Act of 1995, which may include, but are not limited to, statements
regarding our financial outlook, product development, business
prospects, and market and industry trends and conditions, as well
as the Company's strategies, plans, objectives, and goals. These
forward-looking statements are based on current beliefs,
expectations, estimates, forecasts, and projections of, as well as
assumptions made by, and information currently available to, the
Company's management.
The Company assumes no obligation to revise any forward-looking
statement, whether as a result of new information, future events or
otherwise. Accordingly, you should not place reliance on any
forward-looking statement, and all forward-looking statements are
herein qualified by reference to the cautionary statements set
forth above.
1 Lotus Reported Unaudited January Revenues of
NT$1,996 Million, surging 45.4% MoM -
Lotus (lotuspharm.com)
2
https://apps.who.int/gho/data/node.main.MHSUICIDEASDR?lang=en
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaq-nrxp-reports-comments-by-strategic-partner-lotus-pharmaceutical-co-ltd-1975tw-in-recent-financial-report-302058404.html
SOURCE NRx Pharmaceuticals, Inc.